View in EDS

Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.

Saved in:
Bibliographic Details
Title: Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
Authors: Geerlinks AV; Division Hematology and Oncology, Children's Hospital at London Health Sciences Centre, Western University, London, ON, Canada., Scull B; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX., Krupski C; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH., Fleischmann R; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX., Pulsipher MA; Division of Hematology and Oncology, Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT., Eapen M; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Connelly JA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN., Bollard CM; Center for Cancer and Immunology Research, Children's National Hospital and The George Washington University, Washington, DC., Pai SY; National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD., Duncan CN; Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA., Kean LS; Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA., Baker KS; Clinical Research Division, Fred Hutchinson Cancer Center and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA., Burroughs LM; Clinical Research Division, Fred Hutchinson Cancer Center and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA., Andolina JR; Department of Pediatrics, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, NY., Shenoy S; Division of Pediatric Hematology-Oncology, Washington University School of Medicine, St. Louis, MO., Roehrs P; Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA., Hanna R; Department of Pediatric Hematology and Oncology and BMT, Cleveland Clinic, Cleveland, OH., Talano JA; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI., Schultz KR; Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada., Stenger EO; Aflac Center and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA., Lin H; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX., Zoref-Lorenz A; Hematology Institute, Meir Medical Center, Kfar Saba, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH., McClain KL; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX., Jordan MB; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH., Man TK; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX., Allen CE; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX., Marsh RA; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Source: Blood advances [Blood Adv] 2023 Jul 25; Vol. 7 (14), pp. 3725-3734.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37042921
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Geerlinks+AV%22">Geerlinks AV</searchLink>; Division Hematology and Oncology, Children's Hospital at London Health Sciences Centre, Western University, London, ON, Canada.<br /><searchLink fieldCode="AU" term="%22Scull+B%22">Scull B</searchLink>; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Krupski+C%22">Krupski C</searchLink>; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.<br /><searchLink fieldCode="AU" term="%22Fleischmann+R%22">Fleischmann R</searchLink>; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Pulsipher+MA%22">Pulsipher MA</searchLink>; Division of Hematology and Oncology, Primary Children's Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT.<br /><searchLink fieldCode="AU" term="%22Eapen+M%22">Eapen M</searchLink>; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.<br /><searchLink fieldCode="AU" term="%22Connelly+JA%22">Connelly JA</searchLink>; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Bollard+CM%22">Bollard CM</searchLink>; Center for Cancer and Immunology Research, Children's National Hospital and The George Washington University, Washington, DC.<br /><searchLink fieldCode="AU" term="%22Pai+SY%22">Pai SY</searchLink>; National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD.<br /><searchLink fieldCode="AU" term="%22Duncan+CN%22">Duncan CN</searchLink>; Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Kean+LS%22">Kean LS</searchLink>; Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Baker+KS%22">Baker KS</searchLink>; Clinical Research Division, Fred Hutchinson Cancer Center and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Burroughs+LM%22">Burroughs LM</searchLink>; Clinical Research Division, Fred Hutchinson Cancer Center and Department of Pediatrics, University of Washington School of Medicine, Seattle, WA.<br /><searchLink fieldCode="AU" term="%22Andolina+JR%22">Andolina JR</searchLink>; Department of Pediatrics, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, NY.<br /><searchLink fieldCode="AU" term="%22Shenoy+S%22">Shenoy S</searchLink>; Division of Pediatric Hematology-Oncology, Washington University School of Medicine, St. Louis, MO.<br /><searchLink fieldCode="AU" term="%22Roehrs+P%22">Roehrs P</searchLink>; Pediatric Hematology/Oncology, Department of Pediatrics, University of Virginia, Charlottesville, VA.<br /><searchLink fieldCode="AU" term="%22Hanna+R%22">Hanna R</searchLink>; Department of Pediatric Hematology and Oncology and BMT, Cleveland Clinic, Cleveland, OH.<br /><searchLink fieldCode="AU" term="%22Talano+JA%22">Talano JA</searchLink>; Division of Pediatric Hematology/Oncology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.<br /><searchLink fieldCode="AU" term="%22Schultz+KR%22">Schultz KR</searchLink>; Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Stenger+EO%22">Stenger EO</searchLink>; Aflac Center and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA.<br /><searchLink fieldCode="AU" term="%22Lin+H%22">Lin H</searchLink>; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Zoref-Lorenz+A%22">Zoref-Lorenz A</searchLink>; Hematology Institute, Meir Medical Center, Kfar Saba, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.<br /><searchLink fieldCode="AU" term="%22McClain+KL%22">McClain KL</searchLink>; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Jordan+MB%22">Jordan MB</searchLink>; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.<br /><searchLink fieldCode="AU" term="%22Man+TK%22">Man TK</searchLink>; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Allen+CE%22">Allen CE</searchLink>; Division of Pediatric Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, TX.; Texas Children's Cancer and Hematology Center, Texas Children's Hospital, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Marsh+RA%22">Marsh RA</searchLink>; Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2023 Jul 25; Vol. 7 (14), pp. 3725-3734.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37042921
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2022009478
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3725
    Titles:
      – TitleFull: Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Geerlinks AV
      – PersonEntity:
          Name:
            NameFull: Scull B
      – PersonEntity:
          Name:
            NameFull: Krupski C
      – PersonEntity:
          Name:
            NameFull: Fleischmann R
      – PersonEntity:
          Name:
            NameFull: Pulsipher MA
      – PersonEntity:
          Name:
            NameFull: Eapen M
      – PersonEntity:
          Name:
            NameFull: Connelly JA
      – PersonEntity:
          Name:
            NameFull: Bollard CM
      – PersonEntity:
          Name:
            NameFull: Pai SY
      – PersonEntity:
          Name:
            NameFull: Duncan CN
      – PersonEntity:
          Name:
            NameFull: Kean LS
      – PersonEntity:
          Name:
            NameFull: Baker KS
      – PersonEntity:
          Name:
            NameFull: Burroughs LM
      – PersonEntity:
          Name:
            NameFull: Andolina JR
      – PersonEntity:
          Name:
            NameFull: Shenoy S
      – PersonEntity:
          Name:
            NameFull: Roehrs P
      – PersonEntity:
          Name:
            NameFull: Hanna R
      – PersonEntity:
          Name:
            NameFull: Talano JA
      – PersonEntity:
          Name:
            NameFull: Schultz KR
      – PersonEntity:
          Name:
            NameFull: Stenger EO
      – PersonEntity:
          Name:
            NameFull: Lin H
      – PersonEntity:
          Name:
            NameFull: Zoref-Lorenz A
      – PersonEntity:
          Name:
            NameFull: McClain KL
      – PersonEntity:
          Name:
            NameFull: Jordan MB
      – PersonEntity:
          Name:
            NameFull: Man TK
      – PersonEntity:
          Name:
            NameFull: Allen CE
      – PersonEntity:
          Name:
            NameFull: Marsh RA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 07
              Text: 2023 Jul 25
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 7
            – Type: issue
              Value: 14
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1